MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
作者
Yael Chava Cohen,Daniel Morillo,Moshe E. Gatt,Michaël Sébag,Kihyun Kım,Chang‐Ki Min,Albert Oriol,Enrique M. Ocio,Sung‐Soo Yoon,María‐Victoria Mateos,Michael Patvin Chu,Paula Rodríguez‐Otero,Irit Mazza Avivi,Yue Guo,Maria Krevvata,Michelle Peterson,Melissa Jo Beelen,Jill Marie Vanak,Arnob Banerjee,Hila Magen